Induction of Humoral and Cellular Immunity by Intradermal Delivery of SARS-CoV-2 Nucleocapsid Protein Using Dissolvable Microneedles

Figure 1

Schematic illustration of the vaccination with MN NPs: (a) MN NP fabrication process, (b) vaccination process, (c) MN NP administration on mice, image of MN NP patch (d) before deployment (tips present) (scale bar, 5 mm) and (e) after deployment (tips absent) (scale bar, 5 mm), and image of the mouse skin (f) immediately after injection (scale bar, 5 mm) and (g) 24 hours after injection (scale bar, 5 mm).

(a)

(b)

(c)

(d)

(e)

(f)

(g)